Tumor Necrosis Factors
"Tumor Necrosis Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of proteins that were originally identified by their ability to cause NECROSIS of NEOPLASMS. Their necrotic effect on cells is mediated through TUMOR NECROSIS FACTOR RECEPTORS which induce APOPTOSIS.
Descriptor ID |
D048069
|
MeSH Number(s) |
D12.644.276.374.750 D12.644.276.972 D12.776.467.374.750 D12.776.467.972 D23.529.374.750 D23.529.972
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factors".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factors".
This graph shows the total number of publications written about "Tumor Necrosis Factors" by people in this website by year, and whether "Tumor Necrosis Factors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2008 | 1 | 0 | 1 | 2011 | 0 | 2 | 2 | 2014 | 0 | 1 | 1 | 2016 | 1 | 0 | 1 | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factors" by people in Profiles.
-
Overstreet AM, LaTorre DL, Abernathy-Close L, Murphy SF, Rhee L, Boger AM, Adlaka KR, Iverson AM, Bakke DS, Weber CR, Boone DL. The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol. 2018 09; 11(5):1454-1465.
-
Youngquist ST, Shah AP, Rosborough JP, Niemann JT. High Serum Tumor Necrosis Factor Levels in the Early Post-Cardiac Arrest Period Are Associated with Poor Short-Term Survival in a Swine Model of Ventricular Fibrillation. J Interferon Cytokine Res. 2016 10; 36(10):575-579.
-
Xiong H, Pamer EG. Monocytes and infection: modulator, messenger and effector. Immunobiology. 2015 Feb; 220(2):210-4.
-
Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X, Bishop DK, Turka LA, Li XC. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol. 2012 Jan 15; 188(2):892-901.
-
Esteitie R, Emani J, Sharma S, Suskind DL, Baroody FM. Effect of fluticasone furoate on interleukin 6 secretion from adenoid tissues in children with obstructive sleep apnea. Arch Otolaryngol Head Neck Surg. 2011 Jun; 137(6):576-82.
-
Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.
-
Hanauer SB, Sandborn WJ. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2.
-
Liu J, Yang D, Minemoto Y, Leitges M, Rosner MR, Lin A. NF-kappaB is required for UV-induced JNK activation via induction of PKCdelta. Mol Cell. 2006 Feb 17; 21(4):467-80.
-
Mezhir JJ, Schmidt H, Yamini B, Senzer NN, Posner MC, Kufe DW, Weichselbaum RR. Chemo-inducible gene therapy. Anticancer Drugs. 2005 Nov; 16(10):1053-8.
-
Wang J, Fu YX. Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev. 2005 Apr; 204:144-55.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|